--Must See--

Bioinformatics Summer Internship 2024 With Hands-On-Training + Project / Dissertation - 30 Days, 3 Months & 6 Months Duration

Georgia-based biotech Sebacia, a privately held, clinical and commercial stage dermatology and aesthetics company, has now announced the completion of a $36 million funding intended to finish pivotal trials ahead of their FDA submission expected in 2018.

The financing was led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund. New investors accounted for approximately 60 percent of the round and include Salem Partners and other undisclosed investors.

“If approved, the Sebacia treatment would be the first procedure performed by a dermatologist that is intended to provide relief from acne without use of daily pills, lotions and creams,” said Sebacia CEO Anthony Lando.

Sebacia is developing a proprietary microparticle treatment for moderate to severe acne. Sebacia’s microparticles, made of gold and silica, are specially designed to be activated by the light from commonly used hair removal lasers and are placed in a suspension designed to penetrate the sebaceous follicles. In the course of the procedure, they are delivered in a topical suspension specifically designed to work with hair removal or pigmented lesion treatment laser systems. When exposed to a laser pulse, they create a focused photothermal effect in the sebaceous gland and follicle to reduce the

activity level of the gland and the inflammatory lesions that cause acne.

The treatment is intended to be a simple, physician-guided, in-office procedure that could provide an alternative to existing therapies, such as oral antibiotics and isotretinoin.
Sebacia has planned two European trials- the first will study the use of microparticles in patients with facial inflammatory acne, while the second is expected to be a multiple-arm study evaluating the safety and efficacy of the microparticle-and-laser system in patients with acne.

“At this pivotal time, we are grateful for the continued support of our top-tier venture capital syndicate and energized by the addition of Salem Partners and other new investors,” Lando said in the statement. “From intellectual property to extensive clinical experience and a defined clinical path to approval, we believe we have all the pieces to bring Sebacia’s breakthrough treatment for acne to market in Europe and the United States.”

In search of the perfect burger. Serial eater. In her spare time, practises her "Vader Voice". Passionate about dance. Real Weird.